BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesionsData support further development of BT-001 in solid tumors ...
BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesionsData support further development of BT-001 in solid tumors ...
The percentage of participants experiencing burnout decreased significantly after 30 days with the ambient AI scribe from 51.9% to 38.8%. HealthDay News — Use of ambient artificial intelligence (AI) ...
FDA-Registered Home Laser Technology Gains Rapid Adoption During Winter Season as Year-End HSA/FSA Deadlines Drive 290% Search Surge-Podiatrists Report Clinical-Grade Results Without $2,500+ Professio ...
There's something magical about walking through a freshly spritzed cloud of your favorite perfume to complete the applicatio ...